{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:03:49Z","timestamp":1790964229254,"version":"4.1.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00108","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:31:36Z","timestamp":1551159096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors"],"prefix":"10.3389","volume":"9","author":[{"given":"Michael V.","family":"Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Glade Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H.","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.matbio.2015.02.003","article-title":"Proteoglycan form and function: a comprehensive nomenclature of proteoglycans","volume":"42","author":"Iozzo","year":"2015","journal-title":"Matrix Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"19R","DOI":"10.1093\/glycob\/11.3.19R","article-title":"Glypicans in growth control and cancer","volume":"11","author":"Filmus","year":"2001","journal-title":"Glycobiology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","article-title":"Glypican-3: a new target for cancer immunotherapy","volume":"47","author":"Ho","year":"2011","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2017.04.013","article-title":"Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies","volume":"399","author":"Hoseini","year":"2017","journal-title":"Cancer Lett"},{"key":"B5","first-page":"5179","article-title":"Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution","volume":"57","author":"Hsu","year":"1997","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/sj.bjc.6601716","article-title":"Methylation analysis of the glypican 3 gene in embryonal tumours","volume":"90","author":"Boily","year":"2004","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1073\/pnas.96.2.616","article-title":"DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1","volume":"96","author":"Huber","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","article-title":"Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling","volume":"65","author":"Capurro","year":"2005","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1074\/jbc.M410090200","article-title":"The loss of glypican-3 induces alterations in Wnt signaling","volume":"280","author":"Song","year":"2005","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1242\/jcs.140871","article-title":"Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling","volume":"127","author":"Capurro","year":"2014","journal-title":"J Cell Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2016.09.004","article-title":"The heparanase\/heparan sulfate proteoglycan axis: a potential new therapeutic target in sarcomas","volume":"382","author":"Cassinelli","year":"2016","journal-title":"Cancer Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cas.13485","article-title":"Cancer immunotherapy-targeted glypican-3 or neoantigens","volume":"109","author":"Shimizu","year":"2018","journal-title":"Cancer Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.26996","article-title":"Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy","volume":"60","author":"Gao","year":"2014","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4161\/org.4.2.5855","article-title":"Wnt\/\u03b2-catenin signaling in hepatic organogenesis","volume":"4","author":"Nejak-Bowen","year":"2008","journal-title":"Organogenesis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1586\/egh.10.74","article-title":"The Wnt\/beta-catenin signaling pathway in liver biology and disease","volume":"4","author":"Behari","year":"2010","journal-title":"Exp Rev Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4161\/org.4.2.5849","article-title":"Wnt signaling in kidney development and disease","volume":"4","author":"Pulkkinen","year":"2008","journal-title":"Organogenesis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1083\/jcb.200302152","article-title":"Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements","volume":"163","author":"De Cat","year":"2003","journal-title":"J Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13023-014-0138-0","article-title":"Simpson-Golabi-Behmel syndrome types I and II","volume":"9","author":"Tenorio","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1083\/jcb.141.6.1407","article-title":"OCI-5\/GPC3, a glypican encoded by a gene that is mutated in the simpson-golabi-behmel overgrowth syndrome, induces apoptosis in a cell line\u2013specific manner","volume":"141","author":"Gonzalez","year":"1998","journal-title":"J Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ng0396-241","article-title":"Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome","volume":"12","author":"Pilia","year":"1996","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/humu.23612","article-title":"Mutation update for the GPC3 gene involved in Simpson-Golabi-Behmel syndrome and review of the literature","volume":"39","author":"Vuillaume","year":"2018","journal-title":"Hum Mutat."},{"key":"B22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.devcel.2008.03.006","article-title":"Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding","volume":"14","author":"Capurro","year":"2008","journal-title":"Dev Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1083\/jcb.146.1.255","article-title":"Glypican-3\u2013deficient mice exhibit developmental overgrowth and some of the abnormalities typical of simpson-golabi-behmel syndrome","volume":"146","author":"Cano-Gauci","year":"1999","journal-title":"J Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/carcin\/bgn091","article-title":"Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway","volume":"29","author":"Cheng","year":"2008","journal-title":"Carcinogenesis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/jcb.24404","article-title":"Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP","volume":"114","author":"Miao","year":"2013","journal-title":"J Cell Biochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12253-016-0079-0","article-title":"Markers of hippo-pathway activity in tumor forming liver lesions","volume":"23","author":"Reis","year":"2017","journal-title":"Pathol Oncol Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0378-1119(96)00689-0","article-title":"Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5","volume":"188","author":"Lage","year":"1997","journal-title":"Gene"},{"key":"B28","first-page":"58","article-title":"Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies","volume":"36","author":"Lage","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/sj.onc.1207237","article-title":"Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells","volume":"23","author":"Wichert","year":"2004","journal-title":"Oncogene"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17751","DOI":"10.1038\/s41598-017-17665-8","article-title":"A novel cell line based orthotopic xenograft mouse model that recapitulates human hepatoblastoma","volume":"7","author":"Woodfield","year":"2017","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/his.12730","article-title":"Quantification of glypican 3, beta-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution","volume":"67","author":"Zhou","year":"2015","journal-title":"Histopathology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.humpath.2007.06.006","article-title":"Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases","volume":"39","author":"Zynger","year":"2008","journal-title":"Hum Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/modpathol.3800436","article-title":"The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma","volume":"18","author":"Yamauchi","year":"2005","journal-title":"Modern Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2350\/12-06-1216-OA.1","article-title":"Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases","volume":"16","author":"Chan","year":"2013","journal-title":"Pediatr Dev Pathol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1055\/s-0034-1393961","article-title":"Glypican 3 expression in pediatric malignant solid tumors","volume":"25","author":"Kinoshita","year":"2015","journal-title":"Eur J Pediatr Surg"},{"key":"B36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00043426-200111000-00006","article-title":"Glypican-3 expression in Wilms tumor and hepatoblastoma","volume":"23","author":"Toretsky","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2017","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"45932","DOI":"10.1038\/srep45932","article-title":"Glypican 3 as a serum marker for hepatoblastoma","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/PAS.0b013e31815a565a","article-title":"Oncofetal protein glypican-3 Distinguishes Yolk Sac tumor from clear cell carcinoma of the ovary","volume":"32","author":"Esheba","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1309\/8DN7DQRDFB4QNH3N","article-title":"Expression of glypican 3 in ovarian and extragonadal germ cell tumors","volume":"130","author":"Zynger","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1097\/01.pas.0000213322.89670.48","article-title":"Glypican 3: a novel marker in testicular germ cell tumors","volume":"30","author":"Zynger","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I","article-title":"Expression of glypican 3 (GPC3) in embryonal tumors","volume":"89","author":"Saikali","year":"2000","journal-title":"Int J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00428-014-1669-4","article-title":"Glypican 3 overexpression in primary and metastatic Wilms tumors","volume":"466","author":"Tretiakova","year":"2015","journal-title":"Virchows Archiv"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/sj.bjc.6600417","article-title":"Somatic glypican 3 (GPC3) mutations in Wilms' tumour","volume":"86","author":"White","year":"2002","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.humpath.2012.06.014","article-title":"Glypican 3 expression in tumors with loss of SMARCB1\/INI1 protein expression","volume":"44","author":"Kohashi","year":"2013","journal-title":"Hum Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/PAS.0b013e318224d2cd","article-title":"Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins","volume":"35","author":"Venneti","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/jclinpath-2011-200071","article-title":"Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas","volume":"64","author":"Thway","year":"2011","journal-title":"J Clin Pathol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1083\/jcb.201008087","article-title":"Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling","volume":"192","author":"Li","year":"2011","journal-title":"J Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1172\/JCI74270","article-title":"Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth","volume":"124","author":"Knelson","year":"2014","journal-title":"J Clin Invest"},{"key":"B50","first-page":"261","article-title":"Glypican-3 expression in primary and metastatic neuroblastoma","volume":"9","author":"Al-Saraireh","year":"2016","journal-title":"JJBS"},{"key":"B51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ccell.2017.08.003","article-title":"Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma","volume":"32","author":"Bosse","year":"2017","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"E6623","DOI":"10.1073\/pnas.1706055114","article-title":"Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0006-291X(03)00908-2","article-title":"Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker","volume":"306","author":"Nakatsura","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B54","first-page":"2129","article-title":"Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression","volume":"61","author":"Okabe","year":"2001","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e1129483","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e1238542","DOI":"10.1080\/2162402X.2016.1238542","article-title":"Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma","volume":"5","author":"Suzuki","year":"2016","journal-title":"Oncoimmunology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e1377872","DOI":"10.1080\/2162402X.2017.1377872","article-title":"Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors","volume":"7","author":"Tsuchiya","year":"2018","journal-title":"Oncoimmunology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9832","DOI":"10.1158\/0008-5472.CAN-08-1973","article-title":"Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer","volume":"68","author":"Ishiguro","year":"2008","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00280-017-3241-9","article-title":"Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)","volume":"79","author":"Abou-Alfa","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-12-2616","article-title":"First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cas.12368","article-title":"Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma","volume":"105","author":"Ikeda","year":"2014","journal-title":"Cancer Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J Hepatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"10436","DOI":"10.18632\/oncotarget.23830","article-title":"Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/bcp.13530","article-title":"Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma","volume":"84","author":"Nakamura","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e11130","DOI":"10.1097\/MD.0000000000011130","article-title":"Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: an updated meta-analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"E1083","DOI":"10.1073\/pnas.1217868110","article-title":"Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma","volume":"110","author":"Feng","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B68","doi-asserted-by":"publisher","first-page":"592","DOI":"10.4161\/mabs.20933","article-title":"High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening","volume":"4","author":"Phung","year":"2012","journal-title":"mAbs"},{"key":"B69","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/hep.27081","article-title":"WNT\/beta-catenin signaling and hepatocellular carcinoma","volume":"60","author":"Wands","year":"2014","journal-title":"Hepatology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0137664","DOI":"10.1371\/journal.pone.0137664","article-title":"Human monoclonal antibody targeting the heparan sulfate chains of glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells","volume":"10","author":"Gao","year":"2015","journal-title":"PLoS ONE"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.1038\/ncomms7536","article-title":"Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis","volume":"6","author":"Gao","year":"2015","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","first-page":"32450","DOI":"10.18632\/oncotarget.10592","article-title":"Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","first-page":"eaal4291","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci Transl Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1158\/1538-7445.AM2017-3653","article-title":"Abstract 3653: combining ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, with chemotherapy profoundly improved antitumor efficacy over its monotherapy in xenograft model","volume":"77","author":"Sano","year":"2017","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1089\/hum.2016.025","article-title":"Redirecting T cells to Glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity","volume":"28","author":"Li","year":"2017","journal-title":"Hum Gene Therapy"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","article-title":"Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database","volume":"188","author":"Moek","year":"2018","journal-title":"Am J Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:31:39Z","timestamp":1551159099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":78,"alternative-id":["10.3389\/fonc.2019.00108"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00108","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"article-number":"108"}}